Study details
Enrolling now
VELA-TEEN Trial
MoonLake Immunotherapeutics AG
NCT IDNCT06768671ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
35
Study length
about 1.2 years
Ages
12–17
Locations
18 sites in AR, CA, DC +11
About this study
Researchers are testing a treatment called sonelokimab to see how it works and if it's safe for adolescents with hidradenitis suppurativa (HS). The trial will last about 452 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Sonelokimab
PhasePhase 3
DrugSonelokimab
Primary goalAdverse events (AEs) following treatment with sonelokimab in adolescents
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
monoclonal antibody
Endpoints
Primary: Adverse events (AEs) following treatment with sonelokimab in adolescents, Discontinuation of sonelokimab treatment due to AEs, Pharmacokinetics (PK) of sonelokimab in adolescents
Secondary: Numerical Rating Scale (NRS) 30